{"id":1013144,"date":"2026-10-23T09:06:53","date_gmt":"2026-10-23T13:06:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/"},"modified":"2026-10-23T09:06:53","modified_gmt":"2026-10-23T13:06:53","slug":"tempus-expands-strategic-collaboration-with-bristol-myers-squibb","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/","title":{"rendered":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb"},"content":{"rendered":"

<\/p>\n

Tempus Expands Strategic Collaboration with Bristol Myers Squibb<\/b><\/p>\n

CHICAGO–(BUSINESS WIRE<\/a>)–Tempus AI, Inc. (NASDAQ: TEM, \u201cTempus\u201d) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, \u201cBMS\u201d), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus\u2019s largest licensors of de-identified oncology data.<\/p>\n

Additionally, BMS will gain access to Tempus\u2019 Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world\u2019s largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train and execute advanced AI models using de-identified data to surface breakthroughs faster and increase the probability of technical success when developing candidate therapies at scale.<\/p>\n

This agreement expands upon the long-standing strategic relationship<\/a> between Tempus and BMS, which includes applying AI and multimodal real-world data to optimize clinical trial design across high-priority oncology programs and neuroscience initiatives.<\/p>\n

“This strategic collaboration is an important step forward in using AI to advance the discovery of new treatment options and potentially improve patient outcomes,\u201d said Eric Lefkofsky, Founder and CEO of Tempus. \u201cBy uniting our vast multimodal data asset with dedicated GPU power inside our Lens Platform, we are equipping BMS with the AI tools necessary to decode complex biology. Together, we aren’t just speeding up drug discovery, we are laying the foundation for a future where precision oncology becomes the standard of care for every patient.”<\/p>\n

About Tempus<\/b><\/p>\n

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world\u2019s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com<\/a>.<\/p>\n

Forward Looking Statements<\/b><\/p>\n

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus\u2019 industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of its collaboration with BMS to advance AI-driven oncology research and drug discovery. In some cases, you can identify forward-looking statements because they contain words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoing to,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.<\/p>\n

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release, including statements about the size of the database, its potential integrations, and its current and future availability, primarily on its current expectations and projections about future events and trends that it believes may affect Tempus\u2019 business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus\u2019 financial performance; the ability to attract and retain customers and partners; managing Tempus\u2019 growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus\u2019 intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled \u201cRisk Factors\u201d in Tempus\u2019 Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261023516440\/en\/<\/a><\/span><\/p>\n

Investor Relations
\n
Kendra Webster
\n
investorrelations@tempus.com<\/a><\/p>\n

\n

Media
\n
Kelli Manalli
\n
media@tempus.com<\/a><\/p>\n

KEYWORDS:<\/b> Illinois United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Data Management Technology Professional Services Other Health Health Pharmaceutical Oncology Research Data Analytics Artificial Intelligence Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Tempus Expands Strategic Collaboration with Bristol Myers Squibb CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM, \u201cTempus\u201d) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, \u201cBMS\u201d), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus\u2019s largest licensors of de-identified oncology data. Additionally, BMS will gain access to Tempus\u2019 Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world\u2019s largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train … <\/p>\n

Continue reading “Tempus Expands Strategic Collaboration with Bristol Myers Squibb”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013144","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTempus Expands Strategic Collaboration with Bristol Myers Squibb - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempus Expands Strategic Collaboration with Bristol Myers Squibb - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tempus Expands Strategic Collaboration with Bristol Myers Squibb CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM, \u201cTempus\u201d) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, \u201cBMS\u201d), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus\u2019s largest licensors of de-identified oncology data. Additionally, BMS will gain access to Tempus\u2019 Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world\u2019s largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train … Continue reading "Tempus Expands Strategic Collaboration with Bristol Myers Squibb"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T13:06:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tempus Expands Strategic Collaboration with Bristol Myers Squibb\",\"datePublished\":\"2026-10-23T13:06:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/\"},\"wordCount\":870,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/\",\"name\":\"Tempus Expands Strategic Collaboration with Bristol Myers Squibb - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-10-23T13:06:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempus Expands Strategic Collaboration with Bristol Myers Squibb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/","og_locale":"en_US","og_type":"article","og_title":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb - Market Newsdesk","og_description":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM, \u201cTempus\u201d) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, \u201cBMS\u201d), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus\u2019s largest licensors of de-identified oncology data. Additionally, BMS will gain access to Tempus\u2019 Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world\u2019s largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train … Continue reading \"Tempus Expands Strategic Collaboration with Bristol Myers Squibb\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-23T13:06:53+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb","datePublished":"2026-10-23T13:06:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/"},"wordCount":870,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/","name":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-10-23T13:06:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261023516440r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempus-expands-strategic-collaboration-with-bristol-myers-squibb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tempus Expands Strategic Collaboration with Bristol Myers Squibb"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013144"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}